CASTLE BIOSCIENCES INC (CSTL) News
Filter CSTL News Items
CSTL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CSTL News Highlights
- CSTL's 30 day story count now stands at 3.
- Over the past 14 days, the trend for CSTL's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about CSTL are SKIN.
Latest CSTL News From Around the Web
Below are the latest news stories about CASTLE BIOSCIENCES INC that investors may wish to consider to help them evaluate CSTL as an investment opportunity.
Castle Biosciences’ Medical Director to Present at the Precision Medicine World Conference 2023FRIENDSWOOD, Texas, January 23, 2023--Castle's medical director, Matthew Goldberg, M.D., F.A.A.D., will present at the Precision Medicine World Conference (PMWC®) 2023 on Jan. 25. |
Data Presentations at 2023 Winter Clinical Dermatology Conference - Hawaii® Support Clinical Value of Castle Biosciences’ Skin Cancer Test PortfolioFRIENDSWOOD, Texas, January 17, 2023--Castle is sharing new data supporting the clinical value of their skin cancer tests at the 2023 Winter Clinical Dermatology Conference - Hawaii®. |
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2022 ResultsFRIENDSWOOD, Texas, January 09, 2023--Castle Biosciences today announced certain unaudited preliminary performance results for the fourth quarter and full-year ended Dec. 31, 2022. |
Castle Biosciences Receives Accreditation from the College of American Pathologists for its Pittsburgh Clinical LaboratoryFRIENDSWOOD, Texas, November 21, 2022--Castle announced that the Accreditation Committee of the College of American Pathologists (CAP) has accredited its clinical laboratory in Pittsburgh. |
Research Published in Melanoma Management Finds that 99% of Patients with Uveal Melanoma Tested with DecisionDx®-UM Gain Value from the ResultsFRIENDSWOOD, Texas, November 17, 2022--Castle announced the publication of a study in collaboration with the MRF to assess patient experiences with prognostic testing in uveal melanoma. |
Castle Biosciences Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx®-SCC in Moderately and Poorly Differentiated Cutaneous Squamous Cell Carcinoma TumorsFRIENDSWOOD, Texas, November 15, 2022--Castle announced new data showing the independent and significant risk-stratification of DecisionDx-SCC in cSCC tumors with ambiguous histology. |
Castle Biosciences Named a Houston Chronicle Top Workplace for the Second Consecutive YearFRIENDSWOOD, Texas, November 14, 2022--Castle Biosciences has been named a Houston Chronicle Top Workplace for the second year in a row. |
Increasing losses over year doesn't faze Castle Biosciences (NASDAQ:CSTL) investors as stock jumps 11% this past weekCastle Biosciences, Inc. ( NASDAQ:CSTL ) shareholders should be happy to see the share price up 11% in the last week... |
Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Tops Revenue EstimatesCastle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of -10% and 7.73%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
Castle Biosciences Announces Third Quarter 2022 ResultsFRIENDSWOOD, Texas, November 02, 2022--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the third quarter and nine months ended Sept. 30, 2022. |